BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nirogacestat readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Nirogacestat\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05879146-3189@assetmemo.bio
DTSTAMP:20261121T005705Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Nirogacestat: Phase 2 readout est. (NCT05879146)
DESCRIPTION:Nirogacestat\, phase 2\, Desmoid Tumors.\nStudy: Evaluation of 
 the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical 
 Study\nEstimated primary completion: 31 January 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/nirogacestat#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05879146
URL:https://assetmemo.bio/drug/nirogacestat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07170644-3189@assetmemo.bio
DTSTAMP:20261121T005705Z
DTSTART;VALUE=DATE:20270528
DTEND;VALUE=DATE:20270529
SUMMARY:Nirogacestat: Phase 2 readout est. (NCT07170644)
DESCRIPTION:Nirogacestat\, phase 2\, Desmoid Tumors.\nStudy: A Study of Nir
 ogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (
 DT/AF)\nEstimated primary completion: 28 May 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/nirogacestat#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07170644
URL:https://assetmemo.bio/drug/nirogacestat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05556798-3189@assetmemo.bio
DTSTAMP:20261121T005705Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Nirogacestat: Phase 1 readout est. (NCT05556798)
DESCRIPTION:Nirogacestat\, phase 1\, Multiple Myeloma.\nStudy: A Study of B
 elantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in P
 eople With Multiple Myeloma That Has Not Responded to Treatment or Has Com
 e Back After Treatment\nEstimated primary completion: October 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/nirogacestat#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05556798
URL:https://assetmemo.bio/drug/nirogacestat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05949099-3189@assetmemo.bio
DTSTAMP:20261121T005705Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Nirogacestat: Phase 2 readout est. (NCT05949099)
DESCRIPTION:Nirogacestat\, phase 2\, Desmoid Tumors.\nStudy: Study of Cryoa
 blation and Nirogacestat for Desmoid Tumor\nEstimated primary completion: 
 1 February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/niro
 gacestat#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05949099
URL:https://assetmemo.bio/drug/nirogacestat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05137054-3189@assetmemo.bio
DTSTAMP:20261121T005705Z
DTSTART;VALUE=DATE:20280325
DTEND;VALUE=DATE:20280326
SUMMARY:Nirogacestat: Phase 1 readout est. (NCT05137054)
DESCRIPTION:Nirogacestat\, phase 1\, Multiple Myeloma.\nStudy: A Study to E
 xamine the Effects of Novel Therapy Linvoseltamab in Combination With Othe
 r Cancer Treatments for Adult Participants With Multiple Myeloma That is R
 esistant to Current Standard of Care Treatments\nEstimated primary complet
 ion: 25 March 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/n
 irogacestat#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05137054
URL:https://assetmemo.bio/drug/nirogacestat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07539454-3189@assetmemo.bio
DTSTAMP:20261121T005705Z
DTSTART;VALUE=DATE:20300217
DTEND;VALUE=DATE:20300218
SUMMARY:Nirogacestat: Phase 2 readout est. (NCT07539454)
DESCRIPTION:Nirogacestat\, phase 2.\nStudy: Nirogacestat in Patients With K
 aposi Sarcoma\nEstimated primary completion: 17 February 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/nirogacestat#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07539454
URL:https://assetmemo.bio/drug/nirogacestat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07176689-3189@assetmemo.bio
DTSTAMP:20261121T005705Z
DTSTART;VALUE=DATE:20310226
DTEND;VALUE=DATE:20310227
SUMMARY:Nirogacestat: Phase 4 readout est. (NCT07176689)
DESCRIPTION:Nirogacestat\, phase 4\, Desmoid Tumors.\nStudy: Nirogacestat i
 n Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
 \nEstimated primary completion: 26 February 2031. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/nirogacestat#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07176689
URL:https://assetmemo.bio/drug/nirogacestat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
